Dianthus Therapeutics Inc. Cash Flow Conversion Efficiency
Dianthus Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.98 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dianthus Therapeutics Inc. (2016–2025)
Cash flow conversion efficiency of Dianthus Therapeutics Inc. from 2016 to 2025. This chart illustrates how Dianthus Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Dianthus Therapeutics Inc. stock price today for real-time trading data and today's change.
Dianthus Therapeutics Inc. Cash Flow Conversion Ratio Explained
Dianthus Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dianthus Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dianthus Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see market value of Dianthus Therapeutics Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shan XI Hua Yang Group New Energy Co Ltd
SHG:600348
|
0.020x |
|
Bumrungrad Hospital Public Company Limited
BK:BH-R
|
0.057x |
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
0.063x |
|
Brookfield Infrastructure Corp
NYSE:BIPC
|
0.268x |
|
TFS Financial Corporation
NASDAQ:TFSL
|
0.017x |
|
COSCO SHIPPING Specialized Carriers Co Ltd
SHG:600428
|
0.108x |
|
AUTO1 Group SE
F:AG1
|
0.289x |
|
Chipbond Technology
TWO:6147
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Dianthus Therapeutics Inc. from 2016 to 2025. Review cash generation quality of Dianthus Therapeutics Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $493.40 Million | $-129.06 Million | -0.262x | -17.93% |
| 2024-12-31 | $352.48 Million | $-78.18 Million | -0.222x | -1.61% |
| 2023-12-31 | $168.87 Million | $-36.86 Million | -0.218x | +44.69% |
| 2022-12-31 | $73.66 Million | $-29.07 Million | -0.395x | -14.48% |
| 2021-12-31 | $172.67 Million | $-59.53 Million | -0.345x | +22.51% |
| 2020-12-31 | $143.91 Million | $-64.02 Million | -0.445x | -10.00% |
| 2019-12-31 | $141.19 Million | $-57.10 Million | -0.404x | -40.63% |
| 2018-12-31 | $145.65 Million | $-41.89 Million | -0.288x | +35.00% |
| 2017-12-31 | $50.32 Million | $-22.26 Million | -0.442x | +38.73% |
| 2016-12-31 | $9.04 Million | $-6.53 Million | -0.722x | -- |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more